Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMT Aimmune Therapeutics	$34.49	$34.46	$10.09 ▼ $37.00	$2.26B	1.76	1.71 million shs	N/A
CORT Corcept Therapeutics	$71.88 -1.8%	$65.28	$22.60 ▼ $117.33	$7.58B	0.15	1.13 million shs	810,038 shs
MDGL Madrigal Pharmaceuticals	$333.91 -2.0%	$325.41	$200.08 ▼ $377.46	$7.37B	-0.69	387,235 shs	416,600 shs
ROIV Roivant Sciences	$11.62 +2.9%	$10.38	$8.73 ▼ $13.06	$8.29B	1.25	5.48 million shs	6.88 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMT Aimmune Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
CORT Corcept Therapeutics	+3.21%	+13.22%	+34.05%	+19.02%	+213.35%
MDGL Madrigal Pharmaceuticals	+2.87%	+12.58%	+3.94%	+4.43%	+69.49%
ROIV Roivant Sciences	+0.89%	+8.35%	+8.77%	+1.44%	+1.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMT Aimmune Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	4.821 of 5 stars	3.5	3.0	0.0	4.2	4.0	4.2	1.9
MDGL Madrigal Pharmaceuticals	3.7477 of 5 stars	2.5	0.0	0.0	4.6	3.6	4.2	0.6
ROIV Roivant Sciences	2.1639 of 5 stars	3.5	1.0	0.0	0.0	3.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMT Aimmune Therapeutics	0.00	N/A	N/A	N/A
CORT Corcept Therapeutics	3.00	Buy	$143.25	99.29% Upside
MDGL Madrigal Pharmaceuticals	3.00	Buy	$409.00	22.49% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	50.60% Upside

Current Analyst Ratings Breakdown

Latest AIMT, ROIV, CORT, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$443.00 ➝ $443.00
4/21/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/3/2025	CORT Corcept Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$128.00 ➝ $131.00
4/1/2025	CORT Corcept Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $142.00
3/31/2025	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$76.00 ➝ $150.00
3/31/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$115.00 ➝ $150.00
3/4/2025	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/27/2025	CORT Corcept Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $78.00
2/27/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00 ➝ $115.00
2/27/2025	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy	$236.00 ➝ $422.00
2/27/2025	MDGL Madrigal Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$378.00 ➝ $469.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMT Aimmune Therapeutics	N/A	N/A	N/A	N/A	$1.66 per share	N/A
CORT Corcept Therapeutics	$675.04M	11.23	$1.06 per share	67.96	$4.92 per share	14.61
MDGL Madrigal Pharmaceuticals	$180.13M	40.93	N/A	N/A	$20.53 per share	16.26
ROIV Roivant Sciences	$122.59M	67.64	N/A	N/A	$7.76 per share	1.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMT Aimmune Therapeutics	-$248.50M	-$3.97	N/A	N/A	N/A	N/A	-164.99%	-89.50%	N/A
CORT Corcept Therapeutics	$106.14M	$1.24	57.05	38.85	N/A	22.35%	24.54%	20.24%	5/5/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$373.63M	-$22.11	N/A	N/A	N/A	N/A	-71.78%	-53.25%	5/1/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.15	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	5/29/2025 (Estimated)

Latest AIMT, ROIV, CORT, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	N/A	N/A	N/A	$177.93 million	N/A
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.66	N/A	N/A	N/A	$112.79 million	N/A
2/26/2025	Q4 2024	CORT Corcept Therapeutics	$0.37	$0.26	-$0.11	$0.26	$200.12 million	$181.89 million
2/26/2025	Q4 2024	MDGL Madrigal Pharmaceuticals	-$4.32	-$2.71	+$1.61	-$2.71	$97.81 million	$103.32 million
2/10/2025	Q3 2025	ROIV Roivant Sciences	-$0.24	-$0.20	+$0.04	$0.23	$4.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMT Aimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMT Aimmune Therapeutics	0.73	7.53	7.40
CORT Corcept Therapeutics	0.01	3.70	3.64
MDGL Madrigal Pharmaceuticals	0.15	5.98	5.93
ROIV Roivant Sciences	N/A	37.91	37.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMT Aimmune Therapeutics	74.47%
CORT Corcept Therapeutics	93.61%
MDGL Madrigal Pharmaceuticals	98.50%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
AIMT Aimmune Therapeutics	13.75%
CORT Corcept Therapeutics	20.50%
MDGL Madrigal Pharmaceuticals	22.80%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMT Aimmune Therapeutics	228	65.45 million	N/A	Optionable
CORT Corcept Therapeutics	300	105.50 million	83.30 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.08 million	16.84 million	Optionable
ROIV Roivant Sciences	860	713.55 million	657.18 million	Optionable

AIMT, ROIV, CORT, and MDGL Headlines

Recent News About These Companies

Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

April 29 at 12:50 PM | insidermonkey.com

Integrated Wealth Concepts LLC Purchases 41,564 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

April 29 at 5:40 AM | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Position Increased by Tower Research Capital LLC TRC

April 29 at 4:46 AM | marketbeat.com

Gilder Gagnon Howe & Co. LLC Acquires Shares of 1,162,986 Roivant Sciences Ltd. (NASDAQ:ROIV)

April 28 at 6:29 AM | marketbeat.com

Syon Capital LLC Buys Shares of 22,814 Roivant Sciences Ltd. (NASDAQ:ROIV)

April 28 at 5:36 AM | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by First Trust Advisors LP

April 28 at 4:26 AM | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Holdings Increased by Two Seas Capital LP

April 27 at 6:28 AM | marketbeat.com

Barclays PLC Buys 110,371 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

April 27 at 3:54 AM | marketbeat.com

Credit Industriel ET Commercial Invests $1.77 Million in Roivant Sciences Ltd. (NASDAQ:ROIV)

April 26, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Holdings Lessened by Adage Capital Partners GP L.L.C.

April 26, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 100,000 Shares of Stock

April 24, 2025 | marketbeat.com

BlackBarn Capital Partners LP Increases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

April 24, 2025 | marketbeat.com

Peak6 LLC Invests $355,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)

April 24, 2025 | marketbeat.com

Cantor Fitzgerald maintains overweight on Roivant Sciences stock

April 23, 2025 | uk.investing.com

Roivant Sciences (NASDAQ:ROIV) Receives "Buy" Rating from HC Wainwright

April 23, 2025 | marketbeat.com

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

April 23, 2025 | seekingalpha.com

Un initié de Roivant Sciences a vendu des actions pour une valeur de 1 022 000 dollars, selon un récent dépôt auprès de la SEC.

April 23, 2025 | zonebourse.com

HC Wainwright Reiterates "Buy" Rating for Roivant Sciences (NASDAQ:ROIV)

April 23, 2025 | americanbankingnews.com

L’action de Roivant Sciences maintient un objectif de 18$ malgré un remaniement de direction

April 22, 2025 | fr.investing.com

Le président de Roivant Sciences, Eric Venker, vend des actions pour 1,02 million

April 22, 2025 | fr.investing.com

Cantor Fitzgerald maintient sa recommandation positive sur l’action Roivant Sciences

April 22, 2025 | fr.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
Robinhood Strategies Could Be a Game-Changer for Young Investors
By Leo Miller | April 12, 2025
View Robinhood Strategies Could Be a Game-Changer for Young Investors

AIMT, ROIV, CORT, and MDGL Company Descriptions

Aimmune Therapeutics NASDAQ:AIMT

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Corcept Therapeutics NASDAQ:CORT

$71.88 -1.35 (-1.84%)

As of 04:00 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$333.91 -6.89 (-2.02%)

As of 04:00 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Roivant Sciences NASDAQ:ROIV

$11.62 +0.33 (+2.92%)

As of 04:00 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time